PML and prostate neoplasm: Promyelocytic leukemia protein (Pml) inactivation and reactivated mitogen-activated protein kinases (MAPK) leads to lethal metastatic tumors from indolent PTEN-null prostate tumors followed by overactivation of sterol responsive element-binding proteins (SREBP) with altered total lipid profiles.